Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.

Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.

Abstract: The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.

Abstract: A drug delivery device may include a cassette with a needle assembly and a cartridge. The cassette is configured to couple and decouple from a reusable module. The device may also comprise an orientation mechanism to orient the cassette in relation to another device, such as a reusable housing. The device may comprise an extendable and retractable needle assembly. The cassette configuration is adapted to have a stopper with a short travel (no more than 14 mm) to deliver 1 mL of medication. The cassette may have a ratio of height to diameter from 2:1 to 1:1. The cassette may include a pair of drivable interfaces for being driven to actuate the stopper to expel medication and to drive the needle assembly between a retracted and extended configuration for controlled fluid communication between the needle and reservoir.

Abstract: Described herein are codon optimized nucleic acid sequences encoding gap junction protein beta 2 (GJB2), and associated genetic elements, for use in recombinant adeno-associated virus (rAAV)-based gene therapy. The rAAV vectors through which GJB2 is packaged can be used for targeted delivery to patients suffering from genetic hearing loss, including patients with autosomal mutations, recessive or dominant, in the GJB2 gene.

Abstract: Methods for determining protein and/or peptide concentration or molecular parameter, such as the extinction coefficient, and uses thereof.

Abstract: Dose detection systems for medication delivery devices are described. One is a module for removable attachment to a dose button of a medication delivery device. A device with a dose detection system is also disclosed. The module includes a processor and at least one measurement sensor operably coupled to the processor and configured to detect the positon of a sensed component within the delivery device. Medication identification system may also be provided with an identification sensor and a light guide member.

Abstract: Provided herein are compounds that are glucocorticoid receptor agonists useful for the treatment of autoimmune and inflammatory diseases, processes for preparing these compounds, and pharmaceutical compositions comprising these compounds.

Abstract: Medication delivery devices are provided having a dose delivery sensing capability. A sensed element is attached to a dose setting member of the device. The sensed element includes surface features radially-spaced from one another. A rotational sensor is attached to an actuator of the device. The rotational sensor includes a movable element that is contactable against the surface features. The rotational sensor is configured to generate a signal in response to the movement of the movable element over the surface features during their rotation. A controller is operatively coupled to the rotational sensor, and in response to receiving the generated signal, the controller is configured to determine a number of the surface features passing the movable element of the rotational sensor during dose delivery. The number can be associated with an amount of dose delivered. Sensing can be provided in a module or integrated in device.